Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 1—January 2015
CME ACTIVITY - Research

Clinical Course and Long-Term Outcome of Hantavirus-Associated Nephropathia Epidemica, Germany

Joerg Latus, Matthias Schwab, Evelina Tacconelli, Friedrich-Michael Pieper, Daniel Wegener, Juergen Dippon, Simon Müller, David Zakim, Stephan Segerer, Daniel Kitterer, Martin Priwitzer, Barbara Mezger, Birgit Walter-Frank, Angela Corea, Albrecht Wiedenmann, Stefan Brockmann, Christoph Pöhlmann, M. Dominik Alscher, and Niko BraunComments to Author 
Author affiliations: Robert-Bosch-Hospital, Stuttgart, Germany (J. Latus, F.-M. Pieper, D. Wegener, D. Zakim, D. Kitterer, C. Pöhlmann, M.D. Alscher, N. Braun); Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart (M. Schwab); University Hospital Tübingen, Germany (M. Schwab, E. Tacconelli); University of Stuttgart, Stuttgart (J. Dippon, S. Müller); University Hospital Zurich, Zurich, Switzerland (S. Segerer); Local Health Authority, Stuttgart (M. Priwitzer, B. Mezger); Local Health Authority, Böblingen, Germany (B. Walter-Frank); Local Health Authority, Esslingen, Germany (A. Corea, A. Wiedenmann); Local Health Authority, Reutlingen, Germany (S. Brockmann)

Main Article

Table 3

Baseline characteristics for 456 participants in a follow-up study to determine the clinical course and long-term outcome of hantavirus-associated nephropathia epidemica, Germany, 2001–2012*

Variable Median value (range) or % patients positive for variable Reference value
Laboratory test
Creatinine, serum 0.9 mg/dL (0.8–1.0) 0.5–1.4 mg/dL
Blood cell counts
Leukocytes 6.7 × 109/L (5.7–7.9) 4.0–11.3 × 109/L
Platelets 231 × 109/L (201–268) >150 × 109/L
Hemoglobin 14.9 g/dL (14.1–15.6) 13–18 g/dL
Hematocrit 0.43 (0.42–0.46) 0.37–0.47
Uric acid 5.2 mg/dL (4.3–6.0) 4.8–5.6 mg/dL
Liver enzymes
Aspartate aminotransferase 21 U/L (17–25) <50 U/L
Alanine aminotransferase 21 U/L (15–30) <50 U/L
Lactate dehydrogenase 158 U/L (142–180) <250 U/L
C-reactive protein 0.1 mg/dL (0.1–0.2) 0.1–0.4 mg/dL
Urinalysis
Proteinuria 7 –
Hematuria 26 –
Leukocyuria 15 –
Presence of bacteria 0 –
Hantavirus-specific antibodies
IgM present 9 –
IgG present
 100
 –
Clinical test
Blood pressure†
Systolic 135 mm Hg (125–148) –
Diastolic 83 mm Hg (76–90) –
Hypertension at first follow-up, 203/456 participants 45 –
Stage 1 hypertension, 98/203 hypertensive patients 48 –
Stage 2 hypertension, 105/203 hypertensive patients 52 –
Hypertension at second follow-up up‡ 23 –
Stage 1 hypertension 66 –
Stage 2 hypertension 34 –
Heart rate
 70 beats/min (59–79)
 –
Use antihypertensive drugs 43 –
Family history of hypertension
 60
 –
Smoke cigarettes/cigars
 33
 –
Concomitant condition
Coronary heart disease 4 –
Peripheral arterial disease 1 –
Heart failure 2 –
Diabetes mellitus 3 –

*Study participants were adults who had received a diagnosis of serologically and clinically confirmed hantavirus infection during 2001–2012 and who later (7–35 mo) participated in a follow-up study. –, not applicable.
†Hypertension stages 1 and 2 were defined according to the classification of blood pressure for adults (26).
‡Includes only those participants who had hypertension at the first follow-up visit. Retesting was done within 8 wk after first follow-up visit.

Main Article

References
  1. Schmaljohn  CS, Dalrymple  JM. Analysis of Hantaan virus RNA: evidence for a new genus of Bunyaviridae. Virology. 1983;131:482–91 . DOIPubMedGoogle Scholar
  2. Krüger  DH, Ulrich  R, Lundkvist  AA. Hantavirus infections and their prevention. Microbes Infect. 2001;3:1129–44. DOIPubMedGoogle Scholar
  3. Peters  CJ, Simpson  GL, Levy  H. Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annu Rev Med. 1999;50:531–45. DOIPubMedGoogle Scholar
  4. Watson  DC, Sargianou  M, Papa  A, Chra  P, Starakis  I, Panos  G. Epidemiology of hantavirus infections in humans: a comprehensive, global overview. Crit Rev Microbiol. 2014;40:261–72. DOIPubMedGoogle Scholar
  5. Ettinger  J, Hofmann  J, Enders  M, Tewald  F, Oehme  RM, Rosenfeld  UM, Multiple synchronous outbreaks of Puumala virus, Germany, 2010. Emerg Infect Dis. 2012;18:1461–4 . DOIPubMedGoogle Scholar
  6. Boone  I, Wagner-Wiening  C, Reil  D, Jacob  J, Rosenfeld  UM, Ulrich  RG, Rise in the number of notified human hantavirus infections since October 2011 in Baden-Wurttemberg, Germany. Euro Surveill. 2012;17:20180 .PubMedGoogle Scholar
  7. Krüger  DH, Ulrich  RG, Hofmann  J. Hantaviruses as zoonotic pathogens in Germany. Dtsch Arztebl Int. 2013;110:461–7 .PubMedGoogle Scholar
  8. Vapalahti  O, Mustonen  J, Lundkvist  A, Henttonen  H, Plyusnin  A, Vaheri  A. Hantavirus infections in Europe. Lancet Infect Dis. 2003;3:653–61. DOIPubMedGoogle Scholar
  9. Krautkrämer  E, Zeier  M, Plyusnin  A. Hantavirus infection: an emerging infectious disease causing acute renal failure. Kidney Int. 2013;83:23–7. DOIPubMedGoogle Scholar
  10. Braun  N, Haap  M, Overkamp  D, Kimmel  M, Alscher  MD, Lehnert  H, Characterization and outcome following Puumala virus infection: a retrospective analysis of 75 cases. Nephrol Dial Transplant. 2010;25:2997–3003. DOIPubMedGoogle Scholar
  11. Hjertqvist  M, Klein  SL, Ahlm  C, Klingstrom  J. Mortality rate patterns for hemorrhagic fever with renal syndrome caused by Puumala virus. Emerg Infect Dis. 2010;16:1584–6. DOIPubMedGoogle Scholar
  12. Makary  P, Kanerva  M, Ollgren  J, Virtanen  MJ, Vapalahti  O, Lyytikainen  O. Disease burden of Puumala virus infections, 1995–2008. Epidemiol Infect. 2010;138:1484–92. DOIPubMedGoogle Scholar
  13. Mustonen  J, Brummer-Korvenkontio  M, Hedman  K, Pasternack  A, Pietila  K, Vaheri  A. Nephropathia epidemica in Finland: a retrospective study of 126 cases. Scand J Infect Dis. 1994;26:7–13. DOIPubMedGoogle Scholar
  14. Settergren  B, Juto  P, Trollfors  B, Wadell  G, Norrby  SR. Hemorrhagic complications and other clinical findings in nephropathia epidemica in Sweden: a study of 355 serologically verified cases. J Infect Dis. 1988;157:380–2. DOIPubMedGoogle Scholar
  15. Rasche  FM, Uhel  B, Kruger  DH, Karges  W, Czock  D, Hampl  W, Thrombocytopenia and acute renal failure in Puumala hantavirus infections. Emerg Infect Dis. 2004;10:1420–5 . DOIPubMedGoogle Scholar
  16. Ala-Houhala  I, Koskinen  M, Ahola  T, Harmoinen  A, Kouri  T, Laurila  K, Increased glomerular permeability in patients with nephropathia epidemica caused by Puumala hantavirus. Nephrol Dial Transplant. 2002;17:246–52. DOIPubMedGoogle Scholar
  17. Niklasson  B, Hellsten  G, LeDuc  J. Hemorrhagic fever with renal syndrome: a study of sequelae following nephropathia epidemica. Arch Virol. 1994;137:241–7. DOIPubMedGoogle Scholar
  18. Mäkelä  S, Ala-Houhala  I, Mustonen  J, Koivisto  AM, Kouri  T, Turjanmaa  V, Renal function and blood pressure five years after Puumala virus–induced nephropathy. Kidney Int. 2000;58:1711–8. DOIPubMedGoogle Scholar
  19. Miettinen  MH, Mäkelä  SM, Ala-Houhala  IO, Huhtala  HS, Koobi  T, Vaheri  AI, Ten-year prognosis of Puumala hantavirus–induced acute interstitial nephritis. Kidney Int. 2006;69:2043–8. DOIPubMedGoogle Scholar
  20. Lähdevirta  J. Nephropathia epidemica in Finland. A clinical histological and epidemiological study. Ann Clin Res. 1971;3:1–54 .PubMedGoogle Scholar
  21. Lähdevirta  J, Collan  Y, Jokinen  EJ, Hiltunen  R. Renal sequelae to nephropathia epidemica. Acta Pathol Microbiol Scand [A]. 1978;86:265–71 .PubMedGoogle Scholar
  22. Rubini  ME, Jablon  S, Mc  DM. Renal residuals of acute epidemic hemorrhagic fever. Arch Intern Med. 1960;106:378–87. DOIPubMedGoogle Scholar
  23. Kleinknecht  D, Rollin  PE. Hypertension after hemorrhagic fever with renal syndrome. Nephron. 1992;61:121. DOIPubMedGoogle Scholar
  24. Krautkrämer  E, Grouls  S, Urban  E, Schnitzler  P, Zeier  M. No gender-related differences in the severity of nephropathia epidemica, Germany. BMC Infect Dis. 2013;13:457. DOIPubMedGoogle Scholar
  25. Pickering  TG, Hall  JE, Appel  LJ, Falkner  BE, Graves  J, Hill  MN, Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45:142–61. DOIPubMedGoogle Scholar
  26. Chobanian  AV, Bakris  GL, Black  HR, Cushman  WC, Green  LA, Izzo  JL Jr, The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72 . DOIPubMedGoogle Scholar
  27. Bellomo  R, Ronco  C, Kellum  JA, Mehta  RL, Palevsky  P. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8:R204–12. DOIPubMedGoogle Scholar
  28. Outinen  TK, Tervo  L, Mäkelä  S, Huttunen  R, Mäenpää  N, Huhtala  H, Plasma levels of soluble urokinase-type plasminogen activator receptor associate with the clinical severity of acute Puumala hantavirus infection. PLoS ONE. 2013;8:e71335. DOIPubMedGoogle Scholar
  29. Outinen  TK, Mäkelä  SM, Ala-Houhala  IO, Huhtala  HS, Hurme  M, Paakkala  AS, The severity of Puumala hantavirus induced nephropathia epidemica can be better evaluated using plasma interleukin-6 than C-reactive protein determinations. BMC Infect Dis. 2010;10:132. DOIPubMedGoogle Scholar
  30. Krautkrämer  E, Grouls  S, Stein  N, Reiser  J, Zeier  M. Pathogenic old world hantaviruses infect renal glomerular and tubular cells and induce disassembling of cell-to-cell contacts. J Virol. 2011;85:9811–23. DOIPubMedGoogle Scholar
  31. Vaheri  A, Strandin  T, Hepojoki  J, Sironen  T, Henttonen  H, Mäkelä  S, Uncovering the mysteries of hantavirus infections. Nat Rev Microbiol. 2013;11:539–50. DOIPubMedGoogle Scholar
  32. Turčinov  D, Puljiz  I, Markotić  A, Kuzman  I, Begovac  J. Clinical and laboratory findings in patients with oliguric and non-oliguric hantavirus haemorrhagic fever with renal syndrome: an analysis of 128 patients. Clin Microbiol Infect. 2013;19:674–9. DOIPubMedGoogle Scholar
  33. Heyman  P, Vaheri  A, Lundkvist  A, Avsic-Zupanc  T. Hantavirus infections in Europe: from virus carriers to a major public-health problem. Expert Rev Anti Infect Ther. 2009;7:205–17. DOIPubMedGoogle Scholar
  34. Hautala  N, Kauma  H, Vapalahti  O, Mahonen  SM, Vainio  O, Vaheri  A, Prospective study on ocular findings in acute Puumala hantavirus infection in hospitalised patients. Br J Ophthalmol. 2011;95:559–62. DOIPubMedGoogle Scholar
  35. Wolf-Maier  K, Cooper  RS, Banegas  JR, Giampaoli  S, Hense  HW, Joffres  M, Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289:2363–9. DOIPubMedGoogle Scholar
  36. Elgh  F, Linderholm  M, Wadell  G, Tarnvik  A, Juto  P. Development of humoral cross-reactivity to the nucleocapsid protein of heterologous hantaviruses in nephropathia epidemica. FEMS Immunol Med Microbiol. 1998;22:309–15. DOIPubMedGoogle Scholar
  37. Elgh  F, Lundkvist  A, Alexeyev  OA, Stenlund  H, Avsic-Zupanc  T, Hjelle  B, Serological diagnosis of hantavirus infections by an enzyme-linked immunosorbent assay based on detection of immunoglobulin G and M responses to recombinant nucleocapsid proteins of five viral serotypes. J Clin Microbiol. 1997;35:1122–30 .PubMedGoogle Scholar
  38. Maes  P, Clement  J, Gavrilovskaya  I, Van Ranst  M. Hantaviruses: immunology, treatment, and prevention. Viral Immunol. 2004;17:481–97. DOIPubMedGoogle Scholar
  39. Klempa  B, Meisel  H, Rath  S, Bartel  J, Ulrich  R, Kruger  DH. Occurrence of renal and pulmonary syndrome in a region of northeast Germany where Tula hantavirus circulates. J Clin Microbiol. 2003;41:4894–7. DOIPubMedGoogle Scholar
  40. Klempa  B, Schutt  M, Auste  B, Labuda  M, Ulrich  R, Meisel  H, First molecular identification of human Dobrava virus infection in central. J Clin Microbiol. 2004;42:1322–5. DOIPubMedGoogle Scholar

Main Article

Page created: December 17, 2014
Page updated: December 17, 2014
Page reviewed: December 17, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external